Federal grant · project grant (b)
Sbir Phase I: Anti-infective Foley Catheters for Long-term Prevention of Catheter-associated Urinary Tract Infections -the Broader Impact/commercial Potential of This Small Business Innovation Research (SBIR) Phase I Project Is a Novel Anti-infective Coating to Mitigate Catheter-associated Urinary Tract Infections (cautis). These Infections Often Lead to Severe Complications, Resulting in an Estimated 13,000 Annual Deaths While Incurring Nearly $6.2 Billion in Direct and Indirect U.s. Healthcare System Costs. the Hybrid Catheter Technology Aims to Provide Continuous Protection Against Infections Caused by Biofilms, Offering Chronic Antimicrobial and Biofilm-repelling Properties Through a Synergistic Combination of Biofilm-repelling and Static Antimicrobial Surface Moieties. the Proposed Catheter Technology Aims to Demonstrate Significant Decreases in Infection Rates, Improved Catheter Longevity, and Broad-spectrum Protection Against Pathogens to Reduce the Risks of Infection Associated With Long-term Catheter Use, Reducing the Reliance of Patients on Antibiotics. the Scope of This Technology's Application Has Broader Potential Beyond Urinary Catheters to Include Other Catheter-based Applications and Acute In-hospital Use Medical Devices. the Overall Technological Objectives Are to Improve Infection Control Practices and Risk Reduction for Many Common U.s. In-hospital Procedures. This Small Business Innovation Research (SBIR) Phase I Project Aims to Develop a Novel Device Surface Coating With Enhanced Anti-pathogen and Biofilm Resistance. the Objective Is to Develop and Validate in Vitro an Innovative Catheter Design That Offers Prolonged Resistance to Biofilm Formation, Superior to Current Single Modality Approaches. During This Phase 1 Project, the Anti-biofilm Properties of Zwitterionic Moieties Will Be Combined With the Durable Static Microbicidal Action of a Gemini-dicationic Moieties Into a Single Coating. Initial Bench Tests at the Materials Level Demonstrate a Significant Reduction in Biofilm Formation Superior to Currently Available Methods. Invitro Testing Will Be Completed on the Novel Combined Mode Material to Demonstrate Reduced Infection Risks Relative to Existing Antimicrobial Foley Catheters. the Proprietary Material Will Then Be Integrated Into Manufacturing Processes to Prevent Infection in Catheter-use Medical Settings. This Award Reflects NSF'S Statutory Mission and Has Been Deemed Worthy of Support Through Evaluation Using the Foundation's Intellectual Merit and Broader Impacts Review Criteria.- Subawards Are Not Planned for This Award.
Committed
$274,982
Loading…
Everything here is this single award's whole record — signed, amended, paid — not a fiscal-year slice. The by-year charts elsewhere split an award across the years it was committed; this page keeps it whole.
Committed is what the government has legally promised on this award so far. Contracts can also carry a ceiling — the maximum if every option is exercised. Unspent ceiling is headroom, not money owed.
The cash actually disbursed against this award. The gap from committed is the disbursement pipeline: promised, not yet cashed.
Each transaction is a signing event — an action that created or changed the award, dated the day it was signed — not a payment. Negative amounts are real: money de-committed at closeout or renegotiation.
One bar, the award’s whole arithmetic: paid out, then committed, not yet paid, then unspent ceiling.